Fidia Farmaceutici S.p.a.

Devis Galesso

Anna Maria Zanellato

Andrea Pastorello

Fabio Bettella

Lanfranco Callegaro

Vittorio Crescenzi

Cristian Guarise

Anna Taglienti

Mauro Pavan

Riccardo Beninatto

Stefano Pluda

Di Meo Chiara

Alba Di Lucia

Chiara Di Meo

A bio-ink for use in 3D printing, the related conjugate and the preparation process of an intermediate consisting of a bifunctional photoreactive linker are described. Said bio-inks are used for the manufacturing of constructs by 3D printing.

Method for 3D printing with a bio-ink

Disclosed are pharmaceutical compositions in gel form comprising a hydrophilic matrix consisting of a hyaluronic acid derivative containing an amide local anaesthetic in base form.

Pharmaceutical compositions for the treatment of postoperative pain

Disclosed is grade 2 sulphated hyaluronic acid having 2 to 60% molar, preferably 15 to 35%, and even more preferably between 20 and 25%, of the carboxyl groups functionalized with dopamine conjugated directly via an amide bond or by means of a spacer having an amino group for the formation of an amide bond with the carboxyl groups of hyaluronic acid and of a carboxyl group for the formation of an amide bond with the amino group of dopamine.

Sulphated hyaluronic acids functionalised with dopamine

The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and antiinflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and antiinflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.

Sulphated hyaluronic acids as regulator agents of the cytokine activity

The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.

The invention discloses pharmaceutical compositions in the form of a dusting powder or dry spray, possessing a high absorbent capacity, painkilling activity and wound-healing action, which compositions consist of croscarmellose sodium, a non-steroidal anti-inflammatory drug (NSAID) and hyaluronic acid, and optionally also contain other pharmacologically active substances and/or excipients. The compositions disclosed herein are suitable for use in the treatment of skin lesions wherein the presence of exudate limits wound healing and causes pain; they are therefore particularly suitable for chronic ulcerous skin lesions of various origins and burns.

Absorbent dressings with painkilling activity

Crosslinked derivatives of polycarboxylated polysaccharides are described, wherein at least one of the polysaccharide chains consists of hyaluronic acid or a derivative thereof, crosslinked by means of reactions of the 'click chemistry' type and their use in the field of viscosupplementation, plastic surgery, oncologic and reconstructive surgery and also as matrices for controlled release systems of biologically and/or pharmacologically active molecules and/or macromolecules.

Hyaluronic acid derivatives obtained via 'click chemistry' crosslinking

The present invention describes a new bioresorbable filler constituted by hyaluronic acid and/or the derivatives thereof structured with/in phospholipid liposomes, which increase the residence time of the starting polymer in situ. Said fillers described herein are substantially intended to increase the soft tissues in aesthetic surgery and dermocosmetics for the correction of mild to medium defects, but because of their special characteristics they can also be used in other fields of application.

Growing community of inventors

Abano Terme, Italy

Devis Galesso